ClinicalTrials.gg
RecruitingNCT07115108RCTUpdated May 13, 2026

Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease

An interventional study of High energy density enteral nutrition and General energy density enteral nutrition in Congenital Heart Disease, Enteral Nutrition and Pediatrics, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 0 Months to 6 Months. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Children's Hospital of Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
0 Months to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Heart Defects, Congenital by Children's Hospital of Fudan University — 3 open to participants now, 3 under way, none of them phase 3. Heart Defects, Congenital · Children's Hospital of Fudan University.

Started
2025
with 2 others
No phase
7 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Heart Defects, Congenital by Children's Hospital of Fudan University, this one is one of 3 that started in 2025, is one of 7 with no phase, and was the 12th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

3 of the 14 studies in Heart Defects, Congenital by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 0 Months to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Defects, Congenital by Children's Hospital of Fudan University, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of high and ordinary energy density enteral nutrition for improving physical growth and brain cognitive development in infants with congenital heart disease after operation, as well as evaluate the safety of interventions.

03

Conditions studied

  • Congenital Heart Disease
  • Enteral Nutrition
  • Pediatrics

Keywords

  • Congenital heart disease
  • Enteral nutrition
  • Pediatrics
04

Who can participate

Ages eligible
0 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with congenital heart disease through symptoms, physical signs, imaging, and ultrasound examinations.
  • Age 0-6 months
  • Children with nutritional risks (defined by STRONGkids: Nutritional risk screening tool for children )
  • Artificial or mixed feeding
  • Open heart surgery under cardiopulmonary bypass
  • The guardians of the children voluntarily participate in this study and sign a written form before the surgery.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with major non cardiac diseases leading to nutritional intake disorders, such as congenital gastrointestinal malformations, preoperative diagnosis of gastroesophageal reflux, genetic diseases related to growth restriction, and various syndromes with chromosomal abnormalities (trisomy 21 syndrome, trisomy 18 syndrome)
  • Abnormal immune system function due to congenital or acquired factors, unable to effectively resist pathogens or eliminate abnormal cells, which can be divided into primary and secondary immunodeficiencies.
  • Any pre - operative history of neurological diseases (e.g., encephalitis, epilepsy).
  • Secondary or primary gastrointestinal infection symptoms such as abdominal distension and diarrhea after surgery.
  • Estimated stay time in the postoperative intensive care unit ≤ 2 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    High energy density enteral nutrition

    High-energy-density enteral nutrition (100 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted. Weight measurements and neurological assessments will be conducted at admission, prior to discharge, and at 1-, 3-, and 6-month intervals post-discharge. The safety of the intervention will be closely monitored throughout the study period.

    Dietary Supplement: High energy density enteral nutrition

  • Active comparator
    General energy density enteral nutrition

    General energy density enteral nutrition (60-88cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted. Weight measurements and neurological assessments will be conducted at admission, prior to discharge, and at 1-, 3-, and 6-month intervals post-discharge. The safety of the intervention will be closely monitored throughout the study period.

    Dietary Supplement: General energy density enteral nutrition

Interventions

  • Dietary supplementHigh energy density enteral nutrition

    High-energy-density enteral nutrition (100 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.

    Also known as: High energy density EN

  • Dietary supplementGeneral energy density enteral nutrition

    General energy density enteral nutrition (60-88 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.

    Also known as: General energy density EN

06

What researchers measure

Primary outcomes

  1. Weight-for-age z score (WAZ)

    WAZ is calculated according to the Chinese child growth curve and cut-offs .It is a statistical index used to assess the nutritional status of children. The physical examination will be conducted by a nurse, and the data will be recorded to one decimal place.

    Time frame: 6th month after discharge

Secondary outcomes

  1. Weight-for-age z score (WAZ)

    WAZ is calculated according to the Chinese child growth curve and cut-offs .It is a statistical index used to assess the nutritional status of children. The physical examination will be conducted by a nurse, and the data will be recorded to one decimal place.

    Time frame: Before discharge, 1st month, 3rd month after discharge

  2. Cognitive development

    The Griffiths mental development scales (GMDs) will be used to repeatedly measure the indicators .The Griffiths scales typically yield a Developmental Quotient (DQ) with an average range of 85-115. The higher the scores, the more advanced development relative to age norms in assessed domains (e.g., motor, language, or cognition).

    Time frame: Before discharge, 1st month, 3rd month, 6th month after discharge

  3. Incidence of subjects with Gastrointestinal mucosal barrier function injury

    Primarily defined by elevation in fecal calprotectin and Inflammatory cytokines level.The reference range for calprotectin is 0-5 μg/g,inflammatory cytokines is ≤20pg/ml.Exceeding this range will be considered as abnormal gastrointestinal mucosal barrier function.

    Time frame: Before discharge, 1 month, 3 months, 6 months after discharge

  4. Albumin level

    Albumin is a rich protein in the blood, which mainly reflects the nutritional status.The reference range for albumin is 39-54g/L.If it is not within this range, it will be judged as abnormal.

    Time frame: Before discharge, 1 month, 3 months, 6 months after discharge

  5. Blood lipid levels

    Blood lipid test is to measure the content of lipids in blood.Blood lipids include total cholesterol(0-5.18mmol/L) and triglycerides(0-1.7mmol/L).If it exceeds the range, it will be considered as abnormal.

    Time frame: Before discharge, 1 month, 3 months, 6 months after discharge

  6. Energy intake (cal/d)

    Calculate the caloric intake for enteral feeding according to the Schofeld formula recommended by the European Society for Pediatric and Neonatal Intensive Care (ESPNIC)

    Time frame: During hospitalization, before discharge, 1 month, 3 months, 6 months after discharge

  7. Enteral Nutrition intake (ml/d)

    Based on the child's weight and the fluid balance in the previous 24 hours, the total fluid intake for the day is calculated. After subtracting the amount of intravenous drug solution, the amount of enteral nutrition formula is obtained. According to the child's gastrointestinal function, the principle of gradual progress is adopted to rationally allocate the single feeding volume and feeding frequency.

    Time frame: During hospitalization, before discharge, 1 month, 3 months, 6 months after discharge

  8. Incidence of malabsorption

    Incidence of malabsorption (as defined by any of the following criteria): abnormal fecal lactose content; abnormal fecal fat content.The diagnosis will be confirmed by fecal examination.

    Time frame: During hospitalization, before discharge, 1 month, 3 months, 6 months after discharge

  9. Incidence of feeding intolerance

    Any of the following condition: 1. Frequent vomiting (≥ 3 times/d); 2.Abdominal distension; 3. Milk volume did not increase or decreased\>3 d; 4. Gastric retention (retention\>1/3 of the previous feeding); 5. Unplanned discontinuation of feeding ≥ 2 times; 6. Diarrhea (stool frequency\>6 times/d)

    Time frame: During hospitalization, before discharge, 1 month, 3 months, 6 months after discharge

  10. Incidence of necrotizing enterocolitis(NEC)

    NEC diagnosed in stage II and III will be recorded.

    Time frame: Before discharge, 1 month, 3 months, 6 months after discharge

  11. Other surgical indications

    Mechanical ventilation time (days), postoperative CCU hospitalization duration (days), total hospitalization duration (days), hospitalization costs (Yuan), and the incidence of poor wound healing will be recorded.

    Time frame: At the day of discharge, an average of 3 week after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 14 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 11, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07115108
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Oct 13, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 13, 2026

Study contacts

Xu Yulu
Contact
xuyulu05@163.com
8602164931532
Gu Ying
Contact
guying0128@ailyun.com
8602164931223

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion